Forte Biosciences Files 8-K for Material Agreement

Ticker: FBRX · Form: 8-K · Filed: Jun 25, 2025 · CIK: 1419041

Sentiment: neutral

Topics: material-agreement, 8-k, corporate-filing

TL;DR

Forte Biosciences filed an 8-K for a material definitive agreement. Big news incoming.

AI Summary

On June 24, 2025, Forte Biosciences, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company, formerly known as Tocagen Inc., is incorporated in Delaware and headquartered in Dallas, Texas.

Why It Matters

This filing indicates a significant business development for Forte Biosciences, potentially impacting its strategic direction and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce significant risks and opportunities, requiring careful evaluation of the terms and implications.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement filed by Forte Biosciences?

The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this summary.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 24, 2025.

What was Forte Biosciences' former company name?

Forte Biosciences, Inc. was formerly known as Tocagen Inc.

Where are Forte Biosciences' principal executive offices located?

The principal executive offices are located at 3060 Pegasus Park Drive, Building 6, Dallas, Texas, 75247.

What is the company's IRS Employer Identification Number?

The IRS Employer Identification Number for Forte Biosciences, Inc. is 261243872.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding Forte Biosciences, Inc. (FBRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing